PathAI’s Post

Think about all the manual, rote things you do as a healthcare professional, on repeat. Think about human error. Think about the quick way years of knowing and understanding cbcs, and how when you're teaching residents and fellows, all of the things that can be extrapolated. Now.. think about the sea of valuable information that we have not even scratched the surface on, as it relates to pharmacogenomics, how drugs effect people differently, and the troves of relation at the different steps of well known molecular pathways, and how we, to this date, act on 'retrospectively' to appreciate when and why something turned out.. to not work like we thought. And on top of that.. the reliance we trust our family's lives in, on the 'know' or 'yet to know' that exists inside the cranium of one individual making decisions on how long you or your loved one will remain in this world, and what the quality of that life looks like. Imagine... if we had a way to amass, aggregate, and unpack what we to date depend on individuals to 'come up with', theorize, test, figure out, and then re group. Oh, and we text with one adjustment or drug at a time... That's today. How do we leverage intelligence--magnitudes higher than what any human brain is able to do in its strongest best functioning hour--to make gains come sooner, for all those deserving. Get what's overdue, here. The lineup is nothing short, of an all in one.

Over the past 30 years, the Tri-Con has covered all aspects of cancer drug and diagnostic development. In the year of Artificial Intelligence, we are excited to offer a full day of sessions and panels addressing the impact of AI on Precision Oncology. Thank you to Douglas Flora, MD, LSSBB, FACCC for helping us organize. We look forward to hearing from thought leaders in the field, including Ezra Cohen, Scott Penberthy, Sanjay Juneja, M.D., Eric Stahlberg, Oscar Puig, Ben Glass, Arturo LoAIza-Bonilla MD, and Sean Khozin.   Please join Cambridge Healthtech Institute’s 31st International Precision Med TRI-CON, March 26-28, 2024 in San Diego. Visit www.triconference.com for detailed program and to register. Our last registration deadline is extended to tomorrow, plus you can use my code “LI200” for additional $200 discount. Look forward to seeing you in sunny San Diego! #precisionmedicine #ai #artificialintelligence #aiinhealthcare #aiinmedicine #aiinnovation #liquidbiopsy #genomics #personalizedmedicine #diagnostics #moleculardiagnostics #precisionhealth #digitalhealth #digitalmedicine #pointofcare #precisiononcology #ngs #circulatingtumorcells #cancerresearch #biomarkers #companiondiagnostics #immunooncology #spatialbiology #singlecell #raredisease #newbornsequencing #mced #earlydetection #genomicmedicine #innovation #cancerdiagnostics

This week, during European Lung Cancer Week, we want to highlight the power of scientific visualization to raise awareness of the disease and its symptoms. Lung cancer remains one of the leading causes of death worldwide, claiming countless lives each year. Early diagnosis can make a big difference in outcomes. At 3DforScience, we know that understanding begins with clear communication. Using advanced 3D animation and scientific illustration tools, we help pharmaceutical and biotech companies effectively communicate the complex aspects of modern medicine. Our services range from 3D animations that illustrate cellular processes and drug mechanisms of action to augmented reality models that allow healthcare professionals to explore organs and pathologies in detail. With these tools, we don't just present information; we make it accessible and easy to understand. In a world where innovation is crucial, scientific visualization is a strategic differentiator for companies looking to lead in healthcare research, development and education. Want to see how we can help your company stand out with impactful visual storytelling? Learn more about us on our website: https://lnkd.in/eNHDsTvf #3DforScience #MedicalInnovation #Innovation #ScienceCommunication #MedicalIllustration #LungCancerAwareness #EuropeanLungCancerWeek #HealthcareCommunication

We're thrilled to announce our participation in this pivotal event in the #oncology world. As a leading AI-based drug discovery company, we are revolutionizing #cancer treatment through advanced #data solutions. Meet our Chief Medical Officer, Prof. Juergen Scheele, MD, PhD, to explore how our cutting-edge technologies can support your clinical development programs. Our Offerings Include: Synthetic Control Arms: Optimize single-arm trials, especially for small biomarker-defined indications.  Comparative Effectiveness Research: Gain insights into drugs with similar mechanisms of action and understand unique indications better.  AI-Driven Data Solutions: Leverage our extensive datasets for machine learning, including molecular, pathology and radiology imaging.  Virtual Patients: Enhancing clinical trials and market authorization with our comprehensive virtual patient models specifically for lung cancer.  We are committed to partnering with global oncology leaders to create impact and support innovative #drug development. If you want to transform your cancer trials, we’re eager to connect at ESMO - European Society for Medical Oncology 2024 or set up a virtual meeting to discuss how we can collaborate.  Prof. Juergen Scheele #LungCancer #ESMO2024 #AIinHealthcare #OncologyInnovation #ClinicalDevelopment

#Researchers from MIT recently created an #Almodel that can #detect #breastcancer 5 years before it develops. Al is going to save so many lives. Here's how it works: → The model analyzed chromatin images from 560 tissue samples (122 patients), identifying 8 distinct cell states across ductal carcinoma in situ (DCIS) stages. → It considers both cellular composition and spatial arrangement, revealing that tissue organization is crucial in predicting disease progression. → The Al uses a convolutional variational autoencoder to learn from simple chromatin staining images, which is cheaper and easier than complex sequencing. → Surprisingly, cell states associated with invasive cancer were detected even in seemingly normal tissue. With current 5-year survival rates for breast cancer at ~90% when detected early, imagine the lives that could be saved with a 5-year head start on treatment. And as groundbreaking as this is, it's only scratching the surface. The impact Al will have on #healthcare within the next decade is likely far greater than most realize. +when detected early, imagine the lives that could be saved with a 5-year head start on treatment. And as groundbreaking as this is, it's only scratching the surface. The impact Al will have on healthcare within the next decade is likely far greater than most realize. #mit #mit #technology #news

Massive Bio is showcasing its groundbreaking AI technology at the ASCO Annual Meeting 2024 - the DLCTMS. Imagine 14,000+ clinical trials at your fingertips, delivering matches in a heartbeat! Revolutionizing cancer care at lightning speed! 🖥️🔬 With AI precision, Massive Bio unlocks a new era of personalization in oncology/hematology. No more trial and error, it's now looking to be more of a trial and triumph as clinicians connect patients to their best hope, flawlessly. Their commitment to innovation isn't just talk, 120K patients and 5K docs are already aboard their journey to smarter, swifter, and more efficient cancer care 💊 Amazing work from the Team at Massive Bio for bringing science fiction to life by utilizing innovative technology! 🤖✅ #MassiveBio #OncologyResearch #HealthcarInnovation #CancerCare #ClinicalTrials #AIHealthcare #ClinicalResearch #LifeScience #ElixirAssociates #StaffingPartner

Well, that's a wrap for #AACR2024! As always, the conference was a milestone event, the first big oncology event of the year, showcasing a remarkable convergence of professionals across all levels of their careers, with a strong emphasis on supporting early career scientists. This year, the conference stood out to me for integrating more AI and spatial biology content than ever, reflecting cutting-edge trends in cancer research. With over 20,000 participants and 7,000+ posters, it highlighted the vast scope of work from basic science to high-impact clinical trials, including the growing importance of data science in understanding and treating cancer. 🎩 Hat tip to the organizers for putting together a fantastic program that is as much to nurture early career scientists as it is to foster collaboration amongst large industry partners. 💡 I'd love to see more of a patient perspective at the next one. There is nothing more motivating than hearing from the people we are attempting to treat. Without it, we may be striving for endpoints that are not of the most value to patients. Many clinicians have the opportunity to hear this perspective daily, but the overwhelming majority of the attendees at this conference do not have that privilege. ❤️ Thanks to those of you who made the conference special for me - not just the folks I have a decades-long working relationship with but also to the new connections I made - I'm looking forward to doing innovative cancer research with you in the coming years! #CancerResearch #AI #SpatialBiology #AACR24

🚀 Excited to Share My Latest Project: Lung Cancer Prediction Using Machine Learning Classification 🚀 🌟 Project Description: I'm thrilled to present my latest project where I've developed a machine learning model to predict the likelihood of an individual having lung cancer. This model leverages various health indicators and demographic information to assist healthcare professionals in the early detection and diagnosis of lung cancer. 🎯 Objective: The primary objective of this project is to create a robust predictive model that can identify the likelihood of lung cancer in individuals. By doing so, the aim is to enable timely interventions and improve patient outcomes, ultimately contributing to better healthcare delivery. This project has been a significant step towards utilizing data science and machine learning for impactful healthcare solutions. The potential to aid in early detection and provide critical insights for healthcare professionals is incredibly motivating. The Project : https://lnkd.in/dHGfcq9d #MachineLearning #DataScience #HealthcareInnovation #LungCancerPrediction #AIinHealthcare #EarlyDetection #HealthTech #CancerResearch #machinelearning #dataanalysis

News from Anabiosi-Data Ltd. We are thrilled to share the first blog post that highlights the journey and vision of Anabiosi-Data, founded in 2023. This post delves into our commitment to transforming cancer care through personalized treatment, backed by advanced AI and ML technologies. 🔍 In 2024, our innovative approaches were recognized with two significant grants from the Ίδρυμα Έρευνας και Καινοτομίας/Research and Innovation Foundation, propelling us further towards our goal of revolutionizing cancer prognosis, diagnosis, and treatment. 👉 Dive into our blog to discover more about our cutting-edge services and the exciting future we envision at Anabiosi-Data. From Data & Biomarker Performance Analysis to sophisticated AI solutions and beyond, learn how we are tailoring our efforts to meet the unique needs of each patient. 🤝 We're on a mission to enhance patient care globally, and we invite you to join us in this transformative journey. Whether you're a researcher, clinician, or enthusiast in the field of oncology and AI, there’s something in our journey for you. Read the full story here: https://lnkd.in/e5M98Pd5 #AnabiosiData #CancerResearch #PersonalizedMedicine #AIHealthcare #Innovation #MachineLearning #Oncology #HealthTech

Summary: The article highlights the importance of integrating clinical, radiological, pathological, and transcriptomic data to enhance the prediction accuracy of immunotherapy outcomes in metastatic non-small cell lung cancer patients. By leveraging machine learning algorithms and multimodal approaches, researchers found that combining multiple data sources significantly improved risk stratification and biomarker development, showcasing the potential for more effective patient care in the future. Hashtags: #NSCLC #immunotherapy #biomarkers #multimodalapproach #patientcare Advice: When exploring treatment options for complex conditions like lung cancer, consider the benefits of integrating different types of data, such as clinical, radiological, and genetic information, to personalize treatment plans and improve patient outcomes. Taking a holistic approach to healthcare can lead to more targeted and effective interventions, ultimately enhancing quality of life for individuals facing serious health challenges. Read more here: https://lnkd.in/e3qYQtHz BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.